In short
Eliglustat tartrate, also known as Genz-112638, is an oral medication being studied in clinical trials for the treatment of Gaucher disease, a genetic disorder that affects the body's ability to break down certain fats. These trials aim to evaluate the efficacy, safety, and long-term effects of eliglustat tartrate in patients with different types of Gaucher disease, including those who have previously been treated with enzyme replacement therapy.
At a glance
- Drug Name
- Eliglustat tartrate (Genz-112638)
- Disease Target
- Gaucher disease (Type 1 and Type 3)
- Mechanism of Action
- Inhibits production of glucosylceramide
- Administration
- Oral capsules (50mg, 100mg, 150mg)
- Dosing Regimen
- Twice daily (BID), with dose adjustments based on plasma concentrations
- Primary Outcomes
- Changes in spleen volume, liver volume, hemoglobin levels, platelet counts
- Secondary Outcomes
- Bone mineral density, quality of life measures, biomarker levels
- Study Populations
- Adults and pediatric patients (12-18 years old)
- Study Durations
- 52 weeks to 9 years (including long-term follow-up)
- Comparators
- Placebo, Imiglucerase (enzyme replacement therapy)
What is Eliglustat Tartrate?
Eliglustat Tartrate, also known by its research name Genz-112638, is an oral medication developed for the treatment of Gaucher disease. It is a small molecule drug that has been designed to be taken by mouth, offering a convenient alternative to enzyme replacement therapies that require intravenous infusions.
How Does Eliglustat Tartrate Work?
Eliglustat Tartrate works by regulating the Gaucher disease process in a unique way. Instead of replacing the missing enzyme (as in enzyme replacement therapy), it decreases the production of a fatty substance called glucosylceramide. In Gaucher disease, this substance accumulates in cells, causing various health problems. By reducing its production, Eliglustat Tartrate helps to prevent the buildup of this harmful substance in the body's cells, particularly in organs like the liver, spleen, and bone marrow.
What Conditions Does Eliglustat Tartrate Treat?
Eliglustat Tartrate is primarily used to treat Gaucher disease Type 1, which is the most common form of this rare genetic disorder. Gaucher disease Type 1 is characterized by the following symptoms:
- Splenomegaly: An enlarged spleen
- Hepatomegaly: An enlarged liver
- Thrombocytopenia: Low platelet count, which can lead to easy bruising and bleeding
- Anemia: Low red blood cell count, causing fatigue and weakness
- Bone disease: Can cause pain, fractures, and other skeletal problems
- Decreased quality of life
Recent research is also exploring the use of Eliglustat Tartrate in treating Gaucher disease Type 3, which is a more severe form that affects the central nervous system.
How is Eliglustat Tartrate Administered?
Eliglustat Tartrate is taken orally in capsule form. The dosage and frequency can vary depending on the individual patient and their response to the medication. Typically, the treatment follows this pattern:
- Initial dose: Usually starts with 50 mg taken twice daily
- Dose adjustment: After 2-4 weeks, the dose may be adjusted based on blood tests that measure the concentration of the drug in the patient's system
- Maintenance dose: Can range from 50 mg to 150 mg twice daily, depending on the patient's needs and how they metabolize the drug
It's important to note that the dosage is carefully monitored and adjusted by healthcare professionals to ensure the best possible treatment outcome for each patient.
How Effective is Eliglustat Tartrate?
Clinical trials have shown promising results for Eliglustat Tartrate in treating Gaucher disease Type 1. The medication has demonstrated effectiveness in:
- Reducing spleen and liver volume
- Increasing hemoglobin levels (improving anemia)
- Increasing platelet counts
- Improving bone health
- Enhancing quality of life for patients
Long-term studies have shown that many patients remain stable on Eliglustat Tartrate treatment for several years, indicating its potential as a long-term management option for Gaucher disease.
What Are the Potential Side Effects?
As with any medication, Eliglustat Tartrate can have side effects. However, in clinical trials, it has generally been well-tolerated by patients. Common side effects may include:
- Headache
- Nausea
- Diarrhea
- Fatigue
It's important to discuss any side effects with your healthcare provider. They can help manage these effects and determine if any adjustments to your treatment plan are necessary.
Ongoing Research and Future Prospects
Research on Eliglustat Tartrate is ongoing, with several clinical trials exploring its use in different patient populations and treatment scenarios. Some areas of current research include:
- Use in pediatric patients: A study is underway to evaluate the efficacy and safety of Eliglustat in children and adolescents (ages 12 to 18) with Gaucher disease Types 1 and 3
- Long-term effectiveness: Studies are continuing to assess the long-term benefits and safety of Eliglustat Tartrate over several years of use
- Comparison with other treatments: Research is comparing Eliglustat Tartrate to existing treatments like enzyme replacement therapy to determine its relative effectiveness and potential advantages
These ongoing studies aim to provide more comprehensive data on the use of Eliglustat Tartrate, potentially expanding its applications and improving treatment outcomes for patients with Gaucher disease.